Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to SARS-CoV-2 in individuals aged 20 years and older – third update

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F22%3A00127692" target="_blank" >RIV/00216224:14110/22:00127692 - isvavai.cz</a>
Result on the web
<a href="https://www.ecdc.europa.eu/sites/default/files/documents/Interim-analysis-COVID-19-vaccine-over-20.pdf" target="_blank" >https://www.ecdc.europa.eu/sites/default/files/documents/Interim-analysis-COVID-19-vaccine-over-20.pdf</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to SARS-CoV-2 in individuals aged 20 years and older – third update
Original language description
This current report builds on previous analyses [3,4,5] and extends the age groups included. An overview of outcomes, study period and age groups included in the analysis are presented in Table 1 Previous ECDC publications on COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2, are available [3,4]. This third update contains vaccine effectiveness results among individuals aged 20 years and older for the Omicron period) for the first time as well as estimates by COVID-19 vaccine product (i.e. Comirnaty and Vaxzevria).
Czech name
—
Czech description
—

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)